Alkermes plc Acquires Avadel Pharmaceuticals plc

Ipsen Acquires Albireo Pharma

January 9, 2023

Biotechnology

Ipsen has agreed to acquire Albireo Pharma in a cash tender offer of $42.00 per share plus a contingent value right (CVR) tied to FDA approval in biliary atresia, in a transaction intended to expand Ipsen's Rare Disease portfolio. The acquisition brings Albireo's approved pediatric liver drug Bylvay (odevixibat) and a pipeline of bile-acid modulators into Ipsen's global R&D and commercial capabilities.

Alcon Acquires EYSUVIS and INVELTYS Commercial Portfolio from Kala Pharmaceuticals

May 23, 2022

Pharmaceuticals

Alcon Inc. agreed to acquire the commercial portfolio and related intellectual property for EYSUVIS and INVELTYS from Kala Pharmaceuticals for an upfront payment of $60 million, with Kala eligible for future commercial milestone payments. The asset sale allows Alcon to expand its ophthalmic drug franchises while enabling Kala to focus on its pipeline (KPI-012) and extend its cash runway.

Alcon Acquires Aerie Pharmaceuticals

August 22, 2022

Pharmaceuticals

Swiss eye-care leader Alcon has acquired Aerie Pharmaceuticals, a Durham, North Carolina-based ophthalmic pharmaceutical company, adding commercial products Rocklatan and Rhopressa as well as a clinical-stage pipeline including AR-15512. The acquisition strengthens Alcon's ophthalmic pharmaceutical capabilities and R&D expertise and is intended to expand distribution and accelerate development of Aerie's portfolio.

AbbVie Acquires Cerevel Therapeutics

December 6, 2023

Biotechnology

AbbVie Inc. acquired Cerevel Therapeutics for $45.00 per share, valuing Cerevel at approximately $8.7 billion, to bolster AbbVie's neuroscience pipeline. The deal adds Cerevel's clinical-stage assets—including emraclidine, tavapadon, CVL-354 and darigabat—and is intended to expand AbbVie's capabilities and commercial potential in psychiatric and neurological disorders.

Danaher Acquires Aldevron for $9.6 Billion

June 17, 2021

Biotechnology

Danaher Corporation entered into a definitive agreement to acquire Aldevron from EQT Private Equity for an enterprise value of approximately USD 9.6 billion. Aldevron, headquartered in Fargo, North Dakota with ~600 employees and additional operations in Madison, Wisconsin, will operate as a standalone company within Danaher's Life Sciences segment to expand Danaher's capabilities in genomic medicine and biologics manufacturing.

Linden Capital Partners Acquires Alcresta Therapeutics

March 12, 2024

Medical Devices

Chicago-based private equity firm Linden Capital Partners has completed its acquisition of Alcresta Therapeutics from a group led by Athyrium Capital, with Bessemer Venture Partners, Frazier Healthcare Partners and HealthQuest Capital also selling (HealthQuest reinvested as a minority shareholder). Linden will work with Alcresta's management and a newly assembled board to support the commercial launch of the next-generation RELiZORB device and accelerate R&D and growth.